160 Participants Needed

Apollo Device for Scleroderma

(ASScERT-QoL Trial)

RT
MM
Overseen ByMaureen M Laffoon, BS
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Robyn T. Domsic, MD, MPH
Must be taking: Immunosuppressives, Vasodilators
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

Will I have to stop taking my current medications?

You can continue taking your current medications if they are immunosuppressive drugs, vasodilators, or medications for pulmonary hypertension, antidepressants, and anxiolytics, as long as you've been on a steady dose for 4 weeks before starting the trial. However, you cannot be on beta-blockers, sedatives, hypnotics, opioids, benzodiazepines, or anti-psychotic medications.

What is the purpose of this trial?

The purpose of this study it to test the efficacy of a wearable device to improve symptom management and maximize qualify of life in systemic Sclerosis (SSc) patients in a randomized trial. Specifically, we will evaluate if the Apollo Neuro device may improve the two specific symptoms highest ranked by patients as affecting qualify of life (fatigue, Raynaud phenomenon) as co-primary outcomes.

Research Team

RT

Robyn T Domsic, MD

Principal Investigator

University of Pittsburgh

Eligibility Criteria

This trial is for individuals with Systemic Sclerosis, a condition that causes hardening and tightening of the skin. Participants should experience fatigue and Raynaud's phenomenon, which involves poor blood flow to certain parts of the body like fingers and toes.

Inclusion Criteria

Baseline score ≥55 on the FACIT-Fatigue scale
Presence of Raynaud phenomenon with ASRAP-SF severity of T-score ≥40
Ability to provide written informed consent
See 4 more

Exclusion Criteria

Pregnant or breastfeeding women
I have diabetes.
I have not had major surgery in the last 8 weeks.
See 7 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants are randomized to receive either the Apollo Neuro device or a sham device, which they will wear daily for 6 weeks

6 weeks

Follow-up

Participants are monitored for changes in fatigue, Raynaud attacks, and quality of life after the treatment phase

4 weeks

Treatment Details

Interventions

  • Apollo Neuro Device
Trial Overview The study is testing the Apollo Neuro Device, a wearable device designed to help manage symptoms related to Systemic Sclerosis. It will be compared against a sham (fake) device to see if it can improve fatigue and Raynaud's phenomenon.
Participant Groups
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Apollo Neuro DeviceExperimental Treatment1 Intervention
Apollo Neuro Device
Group II: Sham DevicePlacebo Group1 Intervention
Study participants will be randomized 1:1 (Apollo Neuro device : Sham device) Devices are identical; however, the sham device will be set to a frequency that has no therapeutic benefits.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Robyn T. Domsic, MD, MPH

Lead Sponsor

Trials
3
Recruited
200+

United States Department of Defense

Collaborator

Trials
940
Recruited
339,000+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security